The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
A comprehensive review on adult onset Still's disease
Abstract
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown etiology usually affecting young adults; spiking fever, arthritis and evanescent rash are commonly observed during the disease. Other frequently observed clinical features include sore throat, hepatomegaly, splenomegaly, lymphadenopathy and serositis. Furthermore, AOSD patients may experience different life-threating complications. Macrophage activation syndrome (MAS) has been reported up to 15% of AOSD patients and it is considered to be the most severe complication of the disease being characterised by high mortality rate. During AOSD, laboratory tests reflect the systemic inflammatory process showing high levels of erythrocyte sedimentation rate and C-reactive protein. In addition, the ferritin levels are typically higher than those observed in other autoimmune, inflammatory, infectious, or neoplastic diseases. Analysing AOSD disease course, 3 different clinical patterns of AOSD have been identified: i. monocyclic pattern, characterised by a systemic single episode; ii. polycyclic pattern, characterised by multiple, ≤ 1 year lasting, flares, alternating with remissions; iii. chronic pattern, related to a persistently active disease with associated polyarthritis. At present, AOSD therapeutic strategy is aimed at targeting pro-inflammatory signs and symptoms, preventing organ damage and life-threating complications and minimising adverse effects of treatment. However, the treatment of AOSD remains largely empirical, lacking controlled clinical trials. High dosages of corticosteroids are usually the first line therapy when the systemic symptoms predominate. Despite this treatment, a large percentage of patients experiences several flares with an evolution toward the chronic disease course and up to 16% of patients die during the follow up, due to AOSD-related complications. On these bases, in the last years, biological agents have been successfully used in refractory cases. Finally, multiple recent lines of evidence have suggested new insights in AOSD pathogenesis unmasking further therapeutic targets. In fact, small molecules, used in experimental MAS models, might represent new therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for classification of adult Still's disease.
Yamaguchi, M., Ohta, A., Tsunematsu, T., Kasukawa, R., Mizushima, Y., Kashiwagi, H., Kashiwazaki, S., Tanimoto, K., Matsumoto, Y., & Ota, T. (1992) · PubMed · Cited by 1,788
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,475
Adult haemophagocytic syndrome
Ramos-Casals, M., Brito-Zerón, P., López-Guillermo, A., Khamashta, M. A., & Bosch, X. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61048-x · Cited by 1,442
Inflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Regulation of ferritin genes and protein
Torti, F. M., & Torti, S. V. (2002) · Blood · doi:10.1182/blood.v99.10.3505 · Cited by 1,173
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors
Gasparyan, A. Y., Ayvazyan, L., Blackmore, H., & Kitas, G. D. (2011) · Rheumatology International · doi:10.1007/s00296-011-1999-3 · Cited by 694
Knovich, M. A., Storey, J. A., Coffman, L. G., Torti, S. V., & Torti, F. M. (2009) · Blood Reviews · doi:10.1016/j.blre.2008.08.001 · Cited by 627
Interleukin‐18: Biological properties and role in disease pathogenesis
Kaplanski, G. (2018) · Immunological Reviews · doi:10.1111/imr.12616 · Cited by 606
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Ushach, I., & Zlotnik, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0316-144r · Cited by 551
Lara, A. R., & Schwarz, M. I. (2010) · Chest · doi:10.1378/chest.08-2084 · Cited by 530
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease
FAUTREL, B., ZING, E., GOLMARD, J.-L., LE MOEL, G., BISSERY, A., RIOUX, C., ROZENBERG, S., PIETTE, J.-C., & BOURGEOIS, P. (2002) · Medicine · doi:10.1097/00005792-200205000-00003 · Cited by 513
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P., & Shoenfeld, Y. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-185 · Cited by 466
Self-citationSerum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
Cohen, L. A., Gutierrez, L., Weiss, A., Leichtmann-Bardoogo, Y., Zhang, D.-L., Crooks, D. R., Sougrat, R., Morgenstern, A., Galy, B., Hentze, M. W., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253815 · Cited by 452
Macrophage activation syndrome in the era of biologic therapy
Grom, A. A., Horne, A., & De Benedetti, F. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.179 · Cited by 448
Diagnosis and management of adult onset Still's disease
Efthimiou, P., Paik, P. K., & Bielory, L. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042143 · Cited by 433
Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Cutting Edge: Priming of NK Cells by IL-18
Chaix, J., Tessmer, M. S., Hoebe, K., Fuséri, N., Ryffel, B., Dalod, M., Alexopoulou, L., Beutler, B., Brossay, L., Vivier, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1627 · Cited by 374
Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease.
Fautrel, B., Moel, G. L., Saint-Marcoux, B., Taupin, P., Vignes, S., Rozenberg, S., Koeger, A. C., Meyer, O., Guillevin, L., Pietté, J. C., et al. (2001) · PubMed · Cited by 316
Magadur-Joly, G., Billaud, E., Barrier, J. H., Pennec, Y. L., Masson, C., Renou, P., & Prost, A. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.7.587 · Cited by 307
Ruddell, R. G., Hoang‐Le, D., Barwood, J. M., Rutherford, P. S., Piva, T. J., Watters, D. J., Santambrogio, P., Arosio, P., & Ramm, G. A. (2009) · Hepatology · doi:10.1002/hep.22716 · Cited by 298
Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Kötter, I., Hachulla, E., Morel, J., Schaeverbeke, T., Hamidou, M. A., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212608 · Cited by 291
New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity
Recalcati, S., Invernizzi, P., Arosio, P., & Cairo, G. (2008) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.11.003 · Cited by 259
Chen, D., Lan, J., Lin, F., & Hsieh, T. (2004) · PubMed · Cited by 259
Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
Adult-Onset Still Disease: Manifestations, Treatment, Outcome, and Prognostic Factors in 57 Patients
Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., Iwaz, J., Ninet, J., Durieu, I., Broussolle, C., & Sève, P. (2014) · Medicine · doi:10.1097/md.0000000000000021 · Cited by 243
Th17 Response and Inflammatory Autoimmune Diseases
Waite, J. C., & Skokos, D. (2012) · International Journal of Inflammation · doi:10.1155/2012/819467 · Cited by 238
The costimulatory role of TIM molecules
Rodriguez‐Manzanet, R., DeKruyff, R., Kuchroo, V. K., & Umetsu, D. T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00772.x · Cited by 221
TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis
Chen, T. T., Li, L., Chung, D.-H., Allen, C. D. C., Torti, S. V., Torti, F. M., Cyster, J. G., Chen, C.-Y., Brodsky, F. M., Niemi, E. C., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042433 · Cited by 219
Fautrel, B., Sibilia, J., Mariette, X., & Combe, B. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024026 · Cited by 218
The Role of IL‐1 β in the Bone Loss during Rheumatic Diseases
Ruscitti, P., Cipriani, P., Carubbi, F., Liakouli, V., Zazzeroni, F., Di Benedetto, P., Berardicurti, O., Alesse, E., & Giacomelli, R. (2015) · Mediators of Inflammation · doi:10.1155/2015/782382 · Cited by 211
Self-citationSerum cytokine profiles in patients with adult onset Still's disease.
Choi, J., Suh, C., Lee, Y. M., Suh, Y.-J., Lee, S.-K., Kim, S.-S., Nahm, D. H., & Park, H. (2003) · PubMed · Cited by 197
Maschalidi, S., Sepulveda, F. E., Garrigue, A., Fischer, A., & de Saint Basile, G. (2016) · Blood · doi:10.1182/blood-2016-02-700013 · Cited by 195
Ferritin in autoimmune diseases
Zandman-Goddard, G., & Shoenfeld, Y. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.01.016 · Cited by 191
Self-citationRAU, M., SCHILLER, M., KRIENKE, S., HEYDER, P., LORENZ, H., & BLANK, N. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100247 · Cited by 187
Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart
Jamilloux, Y., Gerfaud-Valentin, M., Martinon, F., Belot, A., Henry, T., & Sève, P. (2015) · Immunologic Research · doi:10.1007/s12026-014-8561-9 · Cited by 186
Ruscitti, P., Cipriani, P., Masedu, F., Iacono, D., Ciccia, F., Liakouli, V., Guggino, G., Carubbi, F., Berardicurti, O., Di Benedetto, P., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0738-8 · Cited by 178
Self-citationCalprotectin in rheumatic diseases
Ometto, F., Friso, L., Astorri, D., Botsios, C., Raffeiner, B., Punzi, L., & Doria, A. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370216681551 · Cited by 178
Fujii, T. (2001) · Rheumatology · doi:10.1093/rheumatology/40.12.1398 · Cited by 169
Adult-onset Still's Disease; Clinical and Laboratory Features, Treatment and Progress of 45 Cases
(1986) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068061 · Cited by 161
Life-threatening complications of adult-onset Still’s disease
Efthimiou, P., Kadavath, S. M., & Mehta, B. Y. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2487-4 · Cited by 154
Tocilizumab in refractory adult Still's disease
Puéchal, X., Debandt, M., Berthelot, J., Bréban, M., Dubost, J., Fain, O., Kahn, J., Lequen, L., Longy‐Boursier, M., Perdriger, A., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20319 · Cited by 150
Maria, A., le Quellec, A., Jorgensen, C., Touitou, I., Riviére, S., & Guilpain, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.032 · Cited by 147
INCREASED SERUM FERRITIN LEVELS IN ADULT STILL'S DISEASE
Ota, T., Higashi, S., SUZUKI, H., & Eto, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90204-2 · Cited by 143
Interleukin 1 induces ferritin heavy chain in human muscle cells
Wei, Y., Miller, S. C., Tsuji, Y., Torti, S. V., & Torti, F. M. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91466-6 · Cited by 142
Inoue, N., Shimizu, M., Tsunoda, S., Kawano, M., Matsumura, M., & Yachie, A. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.010 · Cited by 142
Ortiz-Sanjuán, F. M., Blanco, R., Calvo-Río, V., Narváez, J., Romero, E. R., Olivé, A., Castañeda, S., Flores, A. G., Hernández, M. V., Mata, C., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38398 · Cited by 141
The role of the interleukin‐1 family in trained immunity
Moorlag, S. J. C. F. M., Röring, R. J., Joosten, L. A. B., & Netea, M. G. (2017) · Immunological Reviews · doi:10.1111/imr.12617 · Cited by 141
Franchini, S., Dagna, L., Salvo, F., Aiello, P., Baldissera, E. M., & Sabbadini, M. G. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27532 · Cited by 139
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Rossi‐Semerano, L., Fautrel, B., Wendling, D., HACHULLA, E., Galeotti, C., Semerano, L., Touitou, I., Koné‐Paut, I., & the MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on the behalf of CRI (Club Rhumatisme et Inflammation) (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0228-7 · Cited by 138
Akinrinmade, O. A., Chetty, S., Daramola, A. K., Islam, M.-U., Thepen, T., & Barth, S. (2017) · Biomedicines · doi:10.3390/biomedicines5030056 · Cited by 130
Adult-onset Still's disease: Advances in the treatment
Castañeda, S., Blanco, R., & González-Gay, M. Á. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.08.003 · Cited by 124
Ankara Rheumatology Study Group, Pay, S., Türkçapar, N., Kalyoncu, M., Şimşek, İ., Beyan, E., Ertenli, İ., Öztürk, M. A., Düzgün, N., Erdem, H., et al. (2005) · Clinical Rheumatology · doi:10.1007/s10067-005-0138-5 · Cited by 117
Giampietro, C., Ridene, M., Lequerré, T., Costedoat-Chalumeau, N., Amoura, Z., Sellam, J., Sibilia, J., Bourgeois, P., Fautrel, B., & Inflammation), O. B. O. T. C. (. R. E. (2012) · Arthritis Care & Research · doi:10.1002/acr.21901 · Cited by 112
Vignes, S., Moël, G. L., Fautrel, B., Wechsler, B., Godeau, P., & Pietté, J. C. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.5.347 · Cited by 108
Colafrancesco, S., Priori, R., Valesini, G., Argolini, L. M., Baldissera, E. M., Bartoloni, E., Cammelli, D., Canestrari, G. B., Cantarini, L., Cavallaro, E. C., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00369 · Cited by 105
Self-citationLaskari, K., Tzioufas, A. G., & Moutsopoulos, H. Μ. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3366 · Cited by 102
New Markers for Adult-Onset Still's Disease
Mitrovic, S., & Fautrel, B. (2017) · Joint Bone Spine · doi:10.1016/j.jbspin.2017.05.011 · Cited by 102
Efficacy of Anakinra in Refractory Adult-Onset Still's Disease
Ortiz-Sanjuán, F. M., Blanco, R., Riancho‐Zarrabeitia, L., Castañeda, S., Olivé, A., Riveros, A., Velloso-Feijoó, M. L., Narváez, J., Moleón, I. J., Maiz, O., et al. (2015) · Medicine · doi:10.1097/md.0000000000001554 · Cited by 101
Treatment of adult-onset Still’s disease: a review
Sève, P., Jamilloux, Y., Gerfaud‐Valentin, M., & Henry, T. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s64951 · Cited by 100
Infliximab in the treatment of adult Still's disease refractory to conventional therapy.
Cavagna, L., Caporali, R. F., Epis, O. M., Bobbio‐Pallavicini, F., & Montecucco, C. (2001) · PubMed · Cited by 98
Bloom, J., Sun, S., & Al‐Abed, Y. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1251582 · Cited by 98
Kokkinos, A. D., Iliopoulos, A., Greka, P., et al. (2004) · Clinical Rheumatology · doi:10.1007/s10067-003-0775-5 · Cited by 96
Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series
Cipriani, P., Ruscitti, P., Carubbi, F., Pantano, I., Liakouli, V., Berardicurti, O., & Giacomelli, R. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2381-5 · Cited by 95
Self-citationLow glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome
Fardet, L., Coppo, P., Kettaneh, A., Dehoux, M., Cabané, J., & Lambotte, O. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23415 · Cited by 95
Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00380 · Cited by 91
Kontzias, A., & Efthimiou, P. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.03.004 · Cited by 90
Cipriani, P., Ruscitti, P., Carubbi, F., Liakouli, V., & Giacomelli, R. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.014 · Cited by 89
Self-citationCytokine Profiles of Macrophage Activation Syndrome Associated with Rheumatic Diseases
MARUYAMA, J., & Inokuma, S. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090662 · Cited by 88
Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease
Chen, D.-Y., Chen, Y., Lan, J.-L., Lin, C., Chen, H.-H., & Hsieh, C.-W. (2010) · Rheumatology · doi:10.1093/rheumatology/keq284 · Cited by 88
Priori, R., Colafrancesco, S., Alessandri, C., Minniti, A., Perricone, C., Iaiani, G., Palazzo, D., & Valesini, G. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130575 · Cited by 87
Ruscitti, P., Cipriani, P., Ciccia, F., Masedu, F., Liakouli, V., Carubbi, F., Berardicurti, O., Guggino, G., Benedetto, P. D., Bartolomeo, S. D., et al. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.09.016 · Cited by 87
Self-citationsCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia
Colafrancesco, S., Priori, R., Alessandri, C., Astorri, E., Perricone, C., Blank, M., Agmon‐Levin, N., Shoenfeld, Y., & Valesini, G. (2014) · Immunologic Research · doi:10.1007/s12026-014-8563-7 · Cited by 83
Self-citationIL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity
Colafrancesco, S., Priori, R., Alessandri, C., Perricone, C., Pendolino, M., Picarelli, G., & Valesini, G. (2012) · International Journal of Inflammation · doi:10.1155/2012/156890 · Cited by 81
On a form of chronic joint disease in children
Still, G. F. (1941) · Archives of Disease in Childhood · doi:10.1136/adc.16.87.156 · Cited by 80
Ferritin in Adult-Onset Still’s Disease: Just a Useful Innocent Bystander?
Mehta, B. Y., & Efthimiou, P. (2012) · International Journal of Inflammation · doi:10.1155/2012/298405 · Cited by 78
Minoia, F., Davì, S., Horne, A., Bovis, F., Demirkaya, E., Akikusa, J., Ayaz, N. A., Al-Mayouf, S. M., Barone, P., Bica, B., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141261 · Cited by 75
Efficacy and safety of biological agents in adult-onset Still’s disease
Cavalli, G., Franchini, S., Aiello, P., Guglielmi, B., Berti, A., Campochiaro, C., Sabbadini, M. G., Baldissera, E. M., & Dagna, L. (2015) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2014.992949 · Cited by 72
Suematsu, R., Ohta, A., Matsuura, E., Takahashi, H., Fujii, T., Horiuchi, T., Minota, S., Ishigatsubo, Y., Ota, T., Takei, S., et al. (2011) · Modern Rheumatology · doi:10.3109/s10165-011-0569-6 · Cited by 72
Piñero, D. J., Hu, J., Cook, B. M., Scaduto, R. C., & Connor, J. R. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00066-5 · Cited by 71
A controlled study of the long-term prognosis of adult still's disease
Sampalis, J. S., Esdaile, J. M., Medsger, T. A., Partridge, A. J., Yeadon, C., Senécal, J., MYHAL, D., Harth, M., Gutkowski, A., Carette, S., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80318-0 · Cited by 68
Han, J. H., Suh, C., Jung, J., Ahn, M., Han, M. H., Kwon, J. E., Yim, H., & Kim, H. (2017) · Scientific Reports · doi:10.1038/srep46652 · Cited by 68
Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis
Priori, R., Barone, F., Alessandri, C., Colafrancesco, S., McInnes, I. B., Pitzalis, C., Valesini, G., & Bombardieri, M. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq397 · Cited by 64
Ahn, S. S., Yoo, B.-W., Jung, S. M., Lee, S., Park, Y., & Song, J. J. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161286 · Cited by 64
Hsieh, C., Chen, Y., Lin, C., Tang, K., Chen, H., Hung, W., Lai, K., & Chen, D. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161354 · Cited by 61
Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases
Batu, E. D., Erden, A., Şeyhoğlu, E., Kilic, L., Büyükaşık, Y., Karadağ, Ö., Bilginer, Y., Bilgen, Ş. A., Akdoğan, A., Kiraz, S., et al. (2016) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2016.1167951 · Cited by 60
Adult Still's Disease Associated with Mycoplasma pneumoniae Infection
Pérez, C., & de Artola, V. M. (2001) · Clinical Infectious Diseases · doi:10.1086/319342 · Cited by 58
Patel, S. V. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.126 · Cited by 58
Giacomelli, R., Ruscitti, P., Alvaro, S., Ciccia, F., Liakouli, V., Benedetto, P. D., Guggino, G., Berardicurti, O., Carubbi, F., Triolo, G., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1168293 · Cited by 56
Self-citationLee, S.-J., Cho, Y., Kim, T., Park, S., Park, D.-J., Jin, H., Lee, S., Kee, S., Kim, N., Yoo, D., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34514 · Cited by 55
Ruscitti, P., Cipriani, P., Benedetto, P. D., Ciccia, F., Liakouli, V., Carubbi, F., Berardicurti, O., Rizzo, A. G., Triolo, G., & Giacomelli, R. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.004 · Cited by 54
Self-citationRuscitti, P., Ursini, F., Cipriani, P., Sarro, G. D., & Giacomelli, R. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1375853 · Cited by 54
Self-citationRuscitti, P., Cipriani, P., Benedetto, P. D., Liakouli, V., Berardicurti, O., Carubbi, F., Ciccia, F., Guggino, G., Triolo, G., & Giacomelli, R. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13057 · Cited by 53
Self-citationTocilizumab in Adult-onset Still’s Disease: the Israeli Experience
Elkayam, O., Jiries, N., Dranitzki, Z., Kivity, S., Lidar, M., Levy, O., Ablin, J. N., Abu‐Shakra, M., Savargyl-Maman, H., Padova, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130881 · Cited by 52
Han, J. H., Suh, C., Jung, J., Nam, J., Kwon, J. E., Yim, H., & Kim, H. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0773-4 · Cited by 49
Park, J.-H., Bae, J. H., Choi, Y.-S., Lee, H., Jun, J., Jung, S. S., Yoo, D., Bae, S., & Kim, T.-H. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.1.137 · Cited by 48
How I treat patients with adult onset Still's disease in clinical practice
Govoni, M., Bortoluzzi, A., Rossi, D., & Modena, V. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.017 · Cited by 47
Iwata, S., & Tanaka, Y. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1189826 · Cited by 45
Colafrancesco, S., Priori, R., & Valesini, G. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1037287 · Cited by 44
Ruscitti, P., Cipriani, P., Benedetto, P. D., Liakouli, V., Carubbi, F., Berardicurti, O., Ciccia, F., Guggino, G., Triolo, G., & Giacomelli, R. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1372194 · Cited by 44
Self-citationChen, D., Chen, Y., Chen, H., Hsieh, C., Lin, C., & Lan, J. (2010) · Connective Tissue Research · doi:10.3109/03008200903461462 · Cited by 43
Ruscitti, P., Cipriani, P., Ciccia, F., Benedetto, P. D., Liakouli, V., Berardicurti, O., Carubbi, F., Guggino, G., Bartolomeo, S. D., Triolo, G., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12826 · Cited by 42
Self-citationKim, H., Han, J. H., Kim, W., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081342 · Cited by 42
Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease
Bannai, E., Yamashita, H., Kaneko, S., Ueda, Y., Ozaki, T., Tsuchiya, H., Takahashi, Y., Kaneko, H., Kano, T., & Mimori, A. (2014) · Modern Rheumatology · doi:10.3109/14397595.2014.899178 · Cited by 40
Chen, D., Chen, Y., Chen, H., Hsieh, C., Gung, N., Hung, W., Tzang, B., & Hsu, T. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8275 · Cited by 33
Ruscitti, P., Ciccia, F., Cipriani, P., Guggino, G., Benedetto, P. D., Rizzo, A., Liakouli, V., Berardicurti, O., Carubbi, F., Triolo, G., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12738 · Cited by 32
Self-citationSeizing the clinical presentation in adult onset Still's disease. An extensive literature review
Narula, N. G., Narula, T., & Abril, A. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.007 · Cited by 28
Sighart, R., Rech, J., Hueber, A. J., Blank, N., Löhr, S., Reis, A., Sticht, H., & Hüffmeier, U. (2017) · Rheumatology International · doi:10.1007/s00296-017-3885-0 · Cited by 28
Alleviating the storm: ruxolitinib in HLH
Rosée, P. G. L. (2016) · Blood · doi:10.1182/blood-2016-02-697151 · Cited by 26
Maclachlan, D., & Tyndall, A. (2000) · Clinical Rheumatology · doi:10.1007/s100670050161 · Cited by 9
BARTONELLA ENDOCARDITIS MIMICKING ADULT STILL’S DISEASE
Clerck, K. F. D., Offel, J. F. V., Vlieghe, E., Marck, E. V., & Stevens, W. J. (2008) · Acta Clinica Belgica · doi:10.1179/acb.2008.030 · Cited by 6
Metadata
- Authors
- Giacomelli, R., Ruscitti, P., & Shoenfeld, Y.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 93
- Pages
- 24-36
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2887530283
- Cited by
- 419
- References
- 115
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.